Microbix identifies specific proteins that allow X and Y sperm cells to be separated
This is the second important milestone in the Semen Sexing Technology(TM) (SST(TM)) development program. Microbix obtained this technology through its acquisition of Sequent Biotechnologies Inc. in September, 2005. Under the terms of that agreement, Sequent's founders are to receive $3 million in common stock of Microbix, payment being staged and contingent upon the achievement of certain milestones that enable entry into the marketplace. With this announcement, Sequent's founders have been issued 1,821,862 common shares of Microbix, representing half of the total potential payment.
Meistgelesene News
Organisationen
Weitere News aus dem Ressort Forschung & Entwicklung
Holen Sie sich die Life-Science-Branche in Ihren Posteingang
Ab sofort nichts mehr verpassen: Unser Newsletter für Biotechnologie, Pharma und Life Sciences bringt Sie jeden Dienstag und Donnerstag auf den neuesten Stand. Aktuelle Branchen-News, Produkt-Highlights und Innovationen - kompakt und verständlich in Ihrem Posteingang. Von uns recherchiert, damit Sie es nicht tun müssen.